• Publications
  • Influence
50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
  • M. Suggitt, M. Bibby
  • Medicine
  • Clinical cancer research : an official journal of…
  • 1 February 2005
The number of anticancer agents that fail in the clinic far outweighs those considered effective, suggesting that the selection procedure for progression of molecules into the clinic requiresExpand
  • 276
  • 8
  • PDF
Differentiation and definition of vascular-targeted therapies.
The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number ofExpand
  • 253
  • 7
  • PDF
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
  • M. Bibby
  • Medicine
  • European journal of cancer
  • 1 April 2004
Considering the enormous effort that has taken place over the years to discover new chemotherapeutic drugs for treating the common cancers, the conventional murine and xenograft test systems used toExpand
  • 258
  • 7
Antimicrobial activity of cecropins.
The lytic peptides, cecropins, were originally isolated from the haemolymph of the giant silk moth, Hyalophora cecropia and possess antibacterial and anticancer activity in vitro. This studyExpand
  • 154
  • 7
  • PDF
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
SummaryThe anti-tumour effects and mechanism of action of combretastatin A-4 and its prodrug, combretastatin A-4 disodium phosphate, were examined in subcutaneous and orthotopically transplantedExpand
  • 197
  • 6
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
EO9 is a novel and fully synthetic bioreductive alkylating indoloquinone. Although structurally-related to mitomycin C, EO9 exhibits a distinct preclinical antitumour profile and there are alsoExpand
  • 98
  • 5
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
The di-sodium phosphate pro-drug of combretastatin-A4(combA-4P) is undergoing Phase 1 clinical trial in the USA and UK. Its mechanism of action is thought to be related to tubulin-binding propertiesExpand
  • 86
  • 4
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Novel 2-(4-aminophenyl)benzothiazoles (e.g., compounds 1 and 2) possess highly selective, potent antitumor properties in vitro and in vivo. Elucidation of the mechanism of action of this structurallyExpand
  • 78
  • 4
  • PDF
Preliminary experimental anticancer activity of cecropins.
The cecropins are a group of peptides that were first isolated from the hemolymph of the giant silk moth, Hyalophora cecropia. In preliminary studies, these novel peptides were shown to be activeExpand
  • 137
  • 3
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
AQ4 (1,4-Bis-{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9, 10-dione) is a prodrug designed to be excluded from cell nuclei until bioreduced in hypoxic cells to AQ4, a DNAExpand
  • 78
  • 3